Medicinal mushrooms can also interact with anticoagulants, immunosuppressants, and hypoglycemic drugs
Plateaued weight loss before reaching maximum If weight loss stalled mid-titration: Likely causes: Normal temporary plateau Not at therapeutic doses yet Inadequate protein intake Metabolic adaptation Solutions: Continue titration (don't stop early!) Increase protein to 1.2g per lb goal weight Add resistance training 4x weekly Track calories (ensure deficit) Wait 4+ weeks before declaring plateau If plateaued at maximum doses (2.4mg + 2.4mg): Normal after 12-16 weeks Body settling at new weight Assess if goal achieved (15-25% loss typical) Consider if more weight loss realistic/healthy May be maintenance weight Not a true plateau if: Still losing (even 0.5 lb/week counts) Lost expected percentage (15-25%) Only been at max dose 4-8 weeks Intolerable side effects at current doses If can't tolerate escalation: Option 1: Slow down titration Stay at current dose 2-4 extra weeks Let body adapt fully Then retry increase Option 2: Reduce one peptide Drop back on the peptide causing most issues Usually cagrilintide (stronger GI effects) Example: Semaglutide 2.4mg + Cagrilintide 1.2mg Still get benefits, better tolerated Option 3: Reduce both peptides Lower target doses (1.7-2.0mg each) Still effective (13-20% weight loss possible) Much better tolerated Option 4: Stop one peptide Continue semaglutide alone (proven effective) Discontinue cagrilintide Still achieve 10-15% weight loss Don't power through severe side effects: Risks malnutrition, dehydration Reduces adherence long-term Better to find tolerable dose Difficulty affording both peptides Budget-friendly alternatives: Option 1: Prioritize semaglutide Semaglutide 2.4mg alone: $150-300/month Delivers 10-15% weight loss Well-proven, cost-effective Option 2: Lower-dose CagriSema Semaglutide 2.4mg + Cagrilintide 1.2mg Total: $300-550/month Still synergistic, more affordable Option 3: Tirzepatide instead Single peptide, dual mechanism $300-500/month 15-22% weight loss (similar to CagriSema) Option 4: Intermittent CagriSema Use CagriSema during weight loss phase (6-12 months) Switch to semaglutide alone for maintenance Saves $200-400/month long-term Use our peptide stack calculator and peptide cost calculator at SeekPeptides to plan affordable protocols
Biased Agonism: Does It Work?# The Evidence So Far# Two drugs in this comparison -- ecnoglutide and CT-388 -- were specifically engineered with biased agonism to improve tolerability: Ecnoglutide (cAMP-biased at GLP-1R): Discontinuation due to AEs: approximately 2%, among the lowest reported for any GLP-1 agonist Weight loss of 13.2% at 40 weeks is competitive with semaglutide-class efficacy The tolerability-to-efficacy ratio appears favorable CT-388 (signal-biased at both GLP-1R and GIPR): Despite very high Phase 1b GI rates during titration (83% nausea), Phase 2 showed only 5.9% AE discontinuation Weight loss of 22.5% at 48 weeks is among the highest in the field The tolerability-to-efficacy ratio is notable: comparable weight loss to tirzepatide with a lower discontinuation rate What the Data Suggest# The biased agonism hypothesis appears to be supported by early clinical data, though with important caveats: Biased agonists do not eliminate GI side effects -- they may reduce their severity and duration The key metric is discontinuation, not incidence -- a drug with high nausea rates but low discontinuation may indicate transient, manageable symptoms Longer and larger trials are needed -- both ecnoglutide and CT-388 have limited Phase 3 data available Patterns and Insights# More Receptors, More Side Effects# A general pattern emerges: adding receptor targets increases both efficacy and GI side effect burden
To make sure we are on the same page, altruistic Mom, is the metaphorical GSH, and the ROS is her child who dropped the ice cream
